Drug Approval | June 22, 2024
Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
This strategic decision will unlock significant value for our scientific and industrial products business
Subscribe To Our Newsletter & Stay Updated
